Secreted factors

• US 7,202,344 B2
• Filed: 10/05/2004
• Issued: 04/10/2007
• Est. Priority Date: 03/31/2000
• Status: Expired due to Term

• Current Assignee: Scios, Inc. (Johnson & Johnson)
• Original Assignee: Scios, Inc. (Johnson & Johnson)
• Inventors: Stanton, Lawrence W., White, R. Tyler
• Primary Examiner(s): Martinell; James
• Application Number:
  US10/959,440
• Publication Number:
  US 20050208605A1
• Time in Patent Office: 917 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/47 from mammals

Abstract

The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO: 1), P00185_D11 (SEQ ID NO: 3), P00188_D12 (SEQ ID NO: 5), P00188_E01 (SEQ ID NO: 7), P00194_G01 (SEQ ID NO: 9), P00194_G05 (SEQ ID NO: 11), P00194_H10 (SEQ ID NO: 13), P00199_D08 (SEQ ID NO: 15), P00203_D04 (SEQ ID NO: 17), P00203_E06 (SEQ ID NO: 19), P00209_F06 (SEQ ID NO: 21), P00219_D02 (SEQ ID NO: 23), P00219_F06 (SEQ ID NO: 25), P00220_H05 (SEQ ID NO: 27), P00222_G03 (SEQ ID NO: 29), P00225_C01 (SEQ ID NO: 32), P00227_D11 (SEQ ID NO: 34), P00228_F03 (SEQ ID NO: 36), P00233_H08 (SEQ ID NO: 38), P00235_G08 (SEQ ID NO: 40), P00239_C11 (SEQ ID NO: 42), P00240_E05 (SEQ ID NO: 45), P00247_A04 (SEQ ID NO: 50), P00248_B04 (SEQ ID NO: 52), P00249_F09 (SEQ ID NO: 54), P00258_A10 (SEQ ID NO: 56), P00262_C10 (SEQ ID NO: 58), P00269_H08 (SEQ ID NO: 62), P00628_H02 (SEQ ID NO: 66), P00629_C08 (SEQ ID NO: 68), P00641_G11 (SEQ ID NO: 71), P00648_E12 (SEQ ID NO: 73), P00697_C03 (SEQ ID NO: 75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.

Claims

1. An antibody or fragment thereof that specifically binds to an antigen selected from the group consisting of:

(a) an antigen encoded by a polynucleotide encoding at least 50 contiguous amino acids from amino acids 1 to 148 of SEQ ID NO;

2;

(b) an antigen encoded by a polynucleotide encoding a polypeptide having at least 75% sequence identity with amino acids 1 to 203 of SEQ ID NO;

2; and

(c) an antigen encoded by a polynucleotide of SEQ ID NO;

1.

2. The antibody or fragment thereof of claim 1, wherein the antibody is a monoclonal antibody.

3. The antibody or fragment thereof of claim 2, wherein the monoclonal antibody is recombinantly produced.

4. The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof is labeled with a detectable marker.

5. The antibody or fragment thereof of claim 4, wherein the detectable marker is alkaline phosphatase.

6. The antibody or fragment thereof of claim 1, wherein the fragment thereof is selected from the group consisting of Fab, F(ab′

)2, Fv and sFv.

7. The antibody or fragment thereof of claim 1, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

8. A composition comprising an antibody or fragment thereof that specifically binds to an antigen selected from the group consisting of:

(a) an antigen encoded by a polynucleotide encoding at least 50 contiguous amino acids from amino acids 1 to 148 of SEQ ID NO;

2;

(b) an antigen encoded by a polynucleotide encoding a polypeptide having at least 75% sequence identity with amino acids 1 to 203 of SEQ ID NO;

2 and

(c) an antigen encoded by a polynucleotide of SEQ ID NO;

1.

9. The composition of claim 8, further comprising a pharmaceutically acceptable carrier.

10. The composition of claim 8, wherein the antibody or fragment thereof is a monoclonal antibody.

11. The composition of claim 8, wherein the antibody or fragment thereof is labeled with a detectable marker.

12. The composition of claim 11, wherein the detectable marker is alkaline phosphatase.

13. The composition of claim 8, wherein the fragment thereof is selected from the group consisting of Fab, F(ab′

)2, Fv and sFv.

14. The composition of claim 8, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

15. A kit comprising:

an antibody or fragment thereof that specifically binds to an antigen selected from the group consisting of an antigen encoded by a polynucleotide encoding at least 50 contiguous amino acids from amino acids 1 to 148 of SEQ ID NO;

2, an antigen encoded by a polynucleotide encoding a polypeptide having at least 75% sequence identity with amino acids 1 to 203 of SEQ ID NO;

2 and an antigen encoded by a polynucleotide of SEQ ID NO;

1.

16. The kit of claim 15, wherein the antibody is a monoclonal antibody.

17. The kit of claim 15, wherein the antibody or fragment thereof is labeled with a detectable marker.

18. The kit of claim 17, wherein the detectable marker is alkaline phosphatase.

19. The kit of claim 15, wherein the fragment thereof is selected from the group consisting of Fab, F(ab′

)2, Fv and sFv.

20. The kit of claim 15, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.